Most retail investors approach the FTSE 100 the same way: they look for stocks that have fallen, check the dividend yield, and buy those with the most familiar names. It is an approach that feels prudent — buying well-known companies that have come down in price — but research consistently shows it underperforms systematically constructed, multi-factor screens by a significant margin.
Professional fund managers do not browse for ideas. They systematically screen the universe of available stocks against multiple criteria simultaneously, eliminating the vast majority of candidates before spending analytical time on the survivors. This guide teaches you that approach: how to screen the FTSE 100 like a professional, using multiple factors in combination rather than in isolation.
The single-metric screening trap is well-documented in academic and practitioner literature. Each popular single-metric screen has a fatal flaw:
The solution is to combine multiple factors that measure different aspects of business quality simultaneously. When a company screens well on all pillars, the confidence in the investment case increases substantially.
Quality metrics measure the structural health and competitive advantage of the business. Key quality indicators include:
Value metrics measure whether you are paying a reasonable price for the quality you are buying. The classic value trap is buying a low-quality business cheaply; the better opportunity is buying a high-quality business at a fair or reasonable price.
Academic research consistently shows that stocks with positive price momentum continue to outperform in the medium term (3-12 months). Combining momentum with quality and value significantly improves the signal-to-noise ratio.
Understanding the FTSE 100's sector composition is essential for contextualising any screen results. The index is heavily concentrated in a few sectors:
| Sector | Approx. Weight | Key Names | Screening Notes |
|---|---|---|---|
| Financials | ~20% | HSBC, Lloyds, Barclays, Aviva | Use ROE and P/Book; different metrics from industrials |
| Energy | ~15% | Shell, BP | Adjust for commodity cycle; use through-cycle earnings |
| Healthcare | ~12% | AstraZeneca, GSK | Focus on pipeline, margins; high R&D distorts near-term P/E |
| Consumer Staples | ~12% | Unilever, Diageo, Reckitt | Stable margins; focus on organic revenue growth |
| Mining | ~10% | Rio Tinto, BHP, Glencore, Anglo | Commodity cycle sensitivity; use EV/EBITDA at mid-cycle |
| Industrials | ~8% | BAE Systems, Rolls-Royce, Experian | Order books, margins, FCF conversion |
| Consumer Discret. | ~5% | Next, JD Sports, B&M | Cyclical; screen at trough rather than peak multiples |
| Other | ~18% | Various | Apply sector-specific criteria |
One of the most common mistakes retail investors make is applying identical screening thresholds across all sectors. The metrics that indicate quality in a pharmaceutical company are fundamentally different from those that indicate quality in a bank or a retailer.
Banks: ROE and Price/Book are the primary metrics. Banks use leverage to generate returns, so their operating margins are not comparable to industrial companies. A bank with 12-15% ROE and 0.8x Price/Book is cheap; the same numbers mean something entirely different for a manufacturer.
Mining companies: Commodity companies' earnings are highly cyclical. Screening for low P/E at the peak of a commodity cycle will give you a misleading signal — those earnings are about to normalise downward. Professional analysts use "mid-cycle" or "normalised" earnings estimates rather than trailing reported earnings.
Pharmaceutical companies: High P/E ratios reflect long-duration earnings streams from patented drugs. A pharma on 20x P/E with a rich pipeline, high margins, and strong FCF conversion may be far better value than a retailer on 10x P/E with thin margins and no pricing power.
The highest-probability investment opportunities in the FTSE 100 consistently come from companies that are simultaneously high-quality and reasonably valued. The combination is rare because the market generally recognises quality and prices it accordingly. But it occurs during:
Finding these opportunities requires a systematic screen that flags quality companies (Pillar 1) trading at below-average valuations (Pillar 2) with no deteriorating momentum signal that would suggest the cheapness is justified (Pillar 3).